Patients & Caregivers
About HAE
Healthcare Professionals
Clinical Trials
Publications
Investors & News
Annual Meeting
Stock Information
News Releases
Event Calendar
Presentations
SEC Filings
Analyst Coverage
Corporate Governance
About
About Us
Senior Management
Board of Directors
Science
Pipeline
Pipeline
Sebetralstat
Oral Factor XIIa Inhibitor
Careers
Careers
Job Openings
Contact
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential On-demand Treatment for Hereditary Angioedema